An investment by Takeda will expand its Grange Castle site’s existing footprint, with the construction of a new standalone containment production facility dedicated to manufacturing its oncology product Ninlaro for global markets.
The largest pharmaceutical company in Japan, Takeda first set up operations in Ireland in 1997 manufacturing products for global markets. In 2002 Takeda chose Dublin as the location for its first active pharmaceutical ingredient (API) facility outside of Japan.
Paul Keogh, plant director at Takeda Ireland Grange Castle said that the additional investment in Ireland demonstrates the confidence and commitment Takeda has in its Irish operation. “We are delighted that Takeda has chosen Ireland for this investment and proud that we have been entrusted with the responsibility to produce and deliver this very important treatment for cancer patients worldwide. We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high quality products from our site.”
Commenting on the investment Martin Shanahan, CEO IDA Ireland, commentted: “Ireland is a globally recognised centre of excellence in life sciences due to the country’s strong regulatory track record and talent availability. Today’s investment by Takeda demonstrates their continued commitment to Ireland.”
The investment will create approximately 40 new jobs.